<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        412-212-19
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ROFLAST 500 mcg
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ROFLUMILAST
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        500
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        µg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        109.2
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="SPIMACO" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 488]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SPIMACO ADDWAEIH
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        R03DX07 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Roflast contains the active substance roflumilast, which is an anti-inflammatory medicine called phosphodiesterase-4 inhibitor. Roflumilast reduces the activity of phosphodiesterase-4, a protein occurring naturally in body cells. When the activity of this protein is reduced, there is less inflammation in the lungs. This helps to stop narrowing of airways occurring in chronic obstructive pulmonary disease (COPD). Thus Roflast eases breathing problems. &nbsp;<br />&nbsp;<br />Roflast is used for maintenance treatment of severe COPD in adults who in the past had frequent worsening of their COPD symptoms (so-called exacerbations) and who have chronic bronchitis. COPD is a chronic disease of the lungs that results in tightening of the airways (obstruction) and swelling and irritation of the walls of the small air passages (inflammation). This leads to symptoms such as coughing, wheezing, chest tightness or difficulty in breathing. Roflast is to be used in addition to bronchodilators.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take Roflast - If you are allergic to roflumilast or any of the other ingredients of this medicine (listed in section 6) &nbsp;- If you have moderate or severe liver problems. &nbsp;<br />&nbsp;<br />Warnings and precautions &nbsp;<br />&nbsp;<br />Talk to your doctor or pharmacist before taking Roflast.&nbsp;<br />&nbsp;<br />Sudden attack of breathlessness &nbsp;Roflast is not intended for the treatment of a sudden attack of breathlessness (acute bronchospasms). In order to relieve a sudden attack of breathlessness it is very important that your doctor provides you with another medicine to be available to you at all times that can cope with such an attack. Roflast will not help you in this situation. &nbsp;<br />&nbsp;<br />Body weight &nbsp;You should check your body weight on a regular basis. Talk to your doctor if, while taking this medicine, you observe an unintentional loss of body weight (not related to a diet or exercise programme). &nbsp;<br />&nbsp;<br />Other diseases &nbsp;Roflast is not recommended if you have one or more of the following diseases: &nbsp;- Severe immunological diseases such as HIV infection, multiple sclerosis (MS), lupus erythematosus (LE) or progressive multifocal leukoencephalopathy (PML) &nbsp;- Severe acute infectious diseases such as tuberculosis, or acute hepatitis &nbsp;- Cancer (except basal-cell carcinoma, a slow-growing type of skin cancer) &nbsp;- Or severe impairment of the heart function &nbsp;<br />&nbsp;<br />There is a lack of relevant experience with Roflast under these conditions. You should talk to your doctor, if you are diagnosed with any of these diseases. &nbsp;<br />&nbsp;<br />Experience is also limited in patients with a previous diagnosis of tuberculosis, viral hepatitis, herpes viral infection or herpes zoster. Please talk to your doctor if you have one of these diseases. &nbsp;<br />&nbsp;<br />Symptoms you should be aware of &nbsp;You may experience diarrhoea, nausea, abdominal pain or headache during the first weeks of treatment with Roflast. Talk to your doctor if these side effects do not resolve within the first weeks of treatment. &nbsp;<br />&nbsp;<br />Roflast is not recommended in patients with a history of depression associated with suicidal thinking or behaviour.You may also experience sleeplessness, anxiety, nervousness, or&nbsp;depressive mood. Before starting treatment with Roflast, inform your doctor if you are suffering from any symptoms of this kind and of any additional medicines you may take since some of those could increase the probability of these side effects. You or your caregiver should also immediately inform your doctor of any changes in behaviour or mood and of any suicidal thoughts you may have. &nbsp;<br />&nbsp;<br />Children and adolescents &nbsp;<br />&nbsp;<br />Roflast should not be used by children and adolescents under 18 years of age. &nbsp;<br />&nbsp;<br />Other medicines and Roflast&nbsp;<br />&nbsp;<br />Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, especially the following: &nbsp;<br />&nbsp;<br />- A medicine containing theophylline (a medicine to treat respiratory diseases), or &nbsp;- A medicine used for treatment of immunological diseases, such as methotrexate, azathioprine, infliximab, etanercept, or oral corticosteroids to be taken long-term. &nbsp;- A medicine containing fluvoxamine (a medicine to treat anxiety disorders and depression), enoxacin (a medicine to treat bacterial infections) or cimetidine (a medicine to treat stomach ulcers or heartburn).&nbsp;<br />&nbsp;<br />The effect of Roflast may be reduced if taken together with rifampicin (an antibiotic medicine) or with phenobarbital, carbamazepine or phenytoin (medicines usually prescribed for the treatment of epilepsy). Ask your doctor for advice. &nbsp;<br />&nbsp;<br />Roflast may be taken with other medicines used in the treatment of COPD such as inhaled or oral corticosteroids or bronchodilators. Do not stop taking these medicines or reduce their dose unless advised by your doctor. &nbsp;</p><p>Pregnancy and breast-feeding &nbsp;Do not take Roflast if you are or plan to become pregnant, think you may be pregnant, or are breast-feeding. You should not become pregnant during treatment with this medicine and should use an effective method of contraception during therapy, because Roflast may be harmful for the unborn baby. &nbsp;<br />&nbsp;<br />Driving and using machines &nbsp;Roflast has no influence on the ability to drive and use machines. &nbsp;<br />&nbsp;<br />Roflast contains lactose &nbsp;If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure. &nbsp;<br />&nbsp;<br />The recommended dose is one 500 micrograms tablet once daily. &nbsp;<br />&nbsp;<br />Swallow the tablet with some water. You may take this medicine with or without food. Take the tablet at the same time every day. &nbsp;<br />&nbsp;<br />You may need to take Roflast for several weeks to achieve its beneficial effect. &nbsp;<br />&nbsp;<br />If you take more Roflast than you should &nbsp;If you have taken more tablets than you should, you may experience the following symptoms: headache, nausea, diarrhoea, dizziness, throbbing of your heart, light-headedness, clamminess and low blood pressure. Tell your doctor or pharmacist straight away. If possible take your medicine and this leaflet with you. &nbsp;<br />&nbsp;<br />If you forget to take Roflast If you forget to take a tablet at the usual time, take the tablet as soon as you remember on the same day. If on one day you have forgotten to take a tablet of Roflast, just carry on the next day with the next tablet as usual. Continue taking your medicine at the usual times. Do not take a double dose to make up for a forgotten dose. &nbsp;<br />&nbsp;<br />If you stop taking Roflast It is important to continue taking Roflast for as long as prescribed by your doctor, even when you have no symptoms, in order to maintain control of your lung function. &nbsp;If you have any further questions on the use of this medicine, ask your doctor or pharmacist.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. &nbsp;You may experience diarrhoea, nausea, stomach ache or headache during the first weeks of treatment with Roflast. Talk to your doctor if these side effects do not resolve within the first weeks of treatment. &nbsp;<br />&nbsp;<br />Some side effects could be serious. In clinical studies and post-marketing experience, rare instances of suicidal thinking and behaviour (including suicide) were reported. Please notify your doctor immediately of any suicidal thoughts you may have. You may also experience sleeplessness (common), anxiety (uncommon), nervousness (rare), panic attack (rare) or depressive mood (rare). &nbsp;<br />&nbsp;In uncommon cases allergic reactions may occur. Allergic reactions may affect the skin and in rare cases cause swelling of the eyelids, face, lips and tongue, possibly leading to difficulties in breathing and/or a drop in blood pressure and accelerated heartbeat. In case of an allergic reaction, stop taking Roflast and contact your doctor immediately, or go immediately to the emergency department in the nearest hospital. Take all your medicines and this leaflet with you and provide full information of your current medications. &nbsp;<br />Other side effects include the following:&nbsp;<br /><strong>Common side effects </strong>(may affect up to 1 in 10 people)</p><p>- diarrhoea, nausea, stomach ache</p><p>&nbsp;- weight decrease, decreased appetite</p><p>- headache&nbsp;<br /><strong>Uncommon side effects </strong>(may affect up to 1 in 100 people)</p><p>- trembling, sensation of spinning head (vertigo), dizziness &nbsp;</p><p>- sensation of rapid or irregular heartbeat (palpitations)</p><p>&nbsp;- gastritis, vomiting</p><p>&nbsp;- reflux of stomach acid to the gullet (acid regurgitations), indigestion</p><p>- rash</p><p>- muscle pain, muscle weakness or cramps &nbsp;</p><p>- back pain &nbsp;</p><p>- feeling of weakness or tiredness, feeling unwell. &nbsp;<br /><strong>Rare side effects</strong> (may affect up to 1 in 1,000 people)</p><p>- male breast enlargement</p><p>&nbsp;- decreased sense of taste &nbsp;</p><p>- respiratory tract infections (excluding pneumonia)</p><p>&nbsp;- bloody stools, constipation &nbsp;</p><p>- elevation of liver or muscle enzymes (seen in blood tests)</p><p>- wheals (urticaria). &nbsp;</p><p><br />Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects you can help provide more information on the safety of this medicine.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children. Store below 30&deg;C.&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. The expiry date refers to the last day of that month. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- The active substance is roflumilast.</p><p>Each film-coated tablet contains 500 micrograms roflumilast.</p><p>&nbsp;- The other ingredients are:</p><p>&nbsp;- Core: Lactose BP 200, Maize Starch, Povidone 30, and Magnesium Stearate.</p><p>- Coating: Hydroxypropyl Methylcellulose, Titanium Dioxide Pharma Grade, Polyethylene Glycol MW 6000, Purified Talc, Iron Oxide Yellow, and Purified Water BP.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Roflast 500 micrograms film-coated tablets are Light yellow to yellowcoloured, round, biconvex film-coated tablets, engraved with “241” on one side and plain on the other side. Each pack contains 30 tablets 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>SPIMACO ADDWAEIH</p><p>AlQassim pharmaceutical plant</p><p>Saudi Pharmaceutical Industries &amp; Medical Appliance Corporation</p><p>Saudi Arabia&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflets is approved in February 2017.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p><br />&nbsp;<br />&nbsp;ﯾﺤﺘﻮي روﻓﻼﺳﺖ ﻋﻠﻰ اﻟﻤﺎدة اﻟﻔﻌﺎﻟﺔ روﻓﻠﻮﻣﯿﻼﺳﺖ، وھﻮ دواء ﻣﻀﺎد ﻟﻼﻟﺘﮭﺎﺑﺎت يدﻋﻰ ﻣﺎﻧﻊ ﻓﻮﺳﻔﻮداﯾﺴﺘﺮﯾﺰ . . 4يقلل&nbsp; روﻓﻼﺳﺖ ﻣﻦ ﻧﺸﺎط ﻓﻮﺳﻔﻮداﯾﺴﺘﺮﯾﺰ ، وھﻮ ﺑﺮوﺗﯿﻦ طﺒﯿﻌﻲ ﻓﻲ ﺧﻼﯾﺎ اﻟﺠﺴﻢ ﻋﻨﺪﻣﺎ يﻗﻞ ﻧﺸﺎط ھﺬا اﻟﺒﺮوﺗﯿﻦ، يﻗﻞ ﻣﻦ اﻟﺘﮭﺎب&nbsp;ﻓﻲ اﻟﺮﺋﺘﯿﻦ .وھﺬا ﯾﺴﺎﻋﺪ ﻋﻠﻰ وﻗﻒ ﺗﻀﯿﯿﻖ اﻟﺸﻌﺐ اﻟﮭﻮاﺋﯿﺔ اﻟﺘﻲ ﺗﺤﺪث ﻓﻲ ﻣﺮض اﻻﻧﺴﺪاد اﻟﺮﺋﻮي اﻟﻤﺰﻣﻦ&nbsp;.(COPD) وھﻜﺬا ﯾﺨﻔﻒ روﻓﻼﺳﺖ ﻣﻦ ﻣﺸﺎﻛﻞ اﻟﺘﻨﻔﺲ. ﯾﺴﺘﺨﺪم روﻓﻼﺳﺖ كﻋﻼج لﻟﻤﺤﺎﻓﻈﺔ ﻋﻠﻰ ﺣﺎﻟﺔ ﻣﺮض اﻻﻧﺴﺪاد اﻟﺮﺋﻮي اﻟﻤﺰﻣﻦ اﻟﺤﺎد ﻓﻲ اﻟﺒﺎﻟﻐﯿﻦ اﻟﺬﯾﻦ ﻛﺎن ﻟﺪﯾﮭﻢ ﻓﻲ اﻟﻤﺎﺿﻲ ﺗﻔﺎﻗﻢات ﻣﺘﻜﺮرة ﻣﻦ &nbsp;أﻋﺮاض ﻣﺮض اﻻﻧﺴﺪاد اﻟﺮﺋﻮي اﻟﻤﺰﻣﻦ ﻣ( ﺎ ﯾﺴﻤﻰاﻟﺘﻔﺎﻗﻢ)واﻟﺬﯾﻦ ﻟﺪﯾﮭﻢ اﻟﺘﮭﺎب اﻟﺸﻌﺐ اﻟﮭﻮاﺋﯿﺔ اﻟﻤﺰﻣﻦ.</p><p>ﻣﺮض اﻻﻧﺴﺪاد اﻟﺮﺋﻮي اﻟﻤﺰﻣﻦ ھﻮ ﻣﺮض ﻣﺰﻣﻦ ﻓﻲ اﻟﺮﺋﺘﯿﻦ وﯾﺆدي إﻟﻰ ﺿﯿﻖ اﻟﺸﻌﺐ اﻟﮭﻮاﺋﯿﺔ (انسداد ) واﻟﻮرم واﻟﺘﮭﯿﺞ&nbsp;ﻓﻲ ﺟﺪران اﻟﻤﻤﺮات اﻟﮭﻮاﺋﯿﺔ اﻟﺼﻐﯿﺮة (اﻟﺘﮭﺎب) .وھﺬا ﯾﺆدي إﻟﻰ أﻋﺮاض ﻣﺜﻞ اﻟﺴﻌﺎل واﻟﺼﻔﯿﺮ ﻋﻨﺪ اﻟﺘﻨﻔﺲ، وﺿﯿﻖ ﻓﻲ اﻟﺼﺪر أو ﺻﻌﻮﺑﺔ ﻓﻲ اﻟﺘﻨﻔﺲ .</p><p>ﯾﺴﺘﺨﺪم روﻓﻼﺳﺖ ﺑﺎﻹﺿﺎﻓﺔ إﻟﻰ ﻣﻮﺳﻌﺎت اﻟﺸﻌﺐ اﻟﮭﻮاﺋﯿﺔ.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>ﻻ ﺗﺘﻨﺎول روﻓﻼﺳﺖ</strong></p><ul><li>&nbsp; إذا ﻛﺎن ﻟﺪﯾﻚ ﺣﺴﺎﺳﯿﺔ ﻣﻦ ﻣﺎدة اﻟﻤﺪرﺟﺔ ﻓﻲ اﻟﻘﺴﻢ 6</li><li>&nbsp;إذا ﻛﺎن ﻟﺪﯾﻚ ﻣﺸﺎﻛﻞ ﻣﺘﻮﺳﻄﺔ أو ﺷﺪﯾﺪة ﻓﻲ اﻟﻜﺒﺪ&nbsp;</li></ul><p>&nbsp;<br />&nbsp;<strong>اﻟﺘﺤﺬﯾﺮات واﻻﺣﺘﯿﺎطﺎت</strong></p><p>ﺗﺤﺪث ﻣﻊ طﺒﯿﺒﻚ ﻗﺒﻞ ﺗﻨﺎول روﻓﻼﺳﺖ :</p><p>ﻧﻮﺑﺎت مفاجئة ﻣﻦ ﺿﯿﻖ ﻓﻲ اﻟﺘﻨﻔﺲ</p><p>ﻟﯿﺲ اﻟﻤﻘﺼﻮد اﺳﺘﺨﺪام روﻓﻼﺳﺖ ﻟﻌﻼج اﻟﻨﻮﺑﺎت المفاجئة&nbsp;&nbsp;ﻣﻦضيق في التنفس (&nbsp; ﺿﯾق اﻟﺷﻌب اﻟﮭواﺋﯾﺔ الحاد )&nbsp;. من اجل&nbsp;&nbsp;ﺗﺨﻔﯿﻒ اﻟﻨﻮﺑﺎت الﻣﻔﺎﺟﺊ ة ﻣﻦ ﺿﯿﻖ اﻟﺘﻨﻔﺲ.</p><p>&nbsp;</p><p>ﻣﻦ اﻟﻤﮭﻢ ﺟﺪا أن ﯾﻮﻓﺮ ﻟﻚ اﻟﻄﺒﯿﺐ دواء آﺧﺮ يكون&nbsp;ﻣﺘﺎح ﻣﻌﻚ ﻓﻲ ﻛﻞ اﻷوﻗﺎت الذي ﯾﻤﻜﻦ أن يﺗﻌﺎﻣﻞ ﻣﻊ ﻣﺜﻞ ھﺬه اﻟﻨﻮﺑﺎت.</p><p>ﻟﻦ ﯾﺴﺎﻋﺪك روﻓﻼﺳﺖ ﻓﻲ ھﺬه اﻟﺤﺎﻟﺔ</p><p><strong>وزن اﻟﺠﺴﻢ</strong></p><p>ﯾﺠﺐ ﻋﻠﯿﻚ اﻟﺘﺤﻘﻖ ﻣﻦ وزن ﺟﺴﻤﻚ ﻋﻠﻰ أﺳﺎس ﻣﻨﺘﻈﻢ .ﺗﺤﺪث ﻣﻊ طﺒﯿﺒﻚ إذا ﻻﺣﻈﺖ ﺧﺴﺎرة ﻏﯿﺮ ﻣﻘﺼﻮدة ﻣﻦ وزن اﻟﺠﺴﻢ )ﻻ ﻋﻼﻗﺔ ﻟﻨﻈﺎم ﻏﺬاﺋﻲ أو ﺑﺮﻧﺎﻣﺞ ﻣﻤﺎرﺳﺔ اﻟﺮﯾﺎﺿﺔ( أﺛﻨﺎء ﺗﻨﺎول ھﺬا اﻟﺪواء</p><p><strong>اﻷﻣﺮاض اﻷﺧﺮى</strong></p><p>ﻻ ﯾﻨﺼﺢ ﺗﻨﺎول روﻓﻼﺳﺖ إذا ﻛﺎن ﻟﺪﯾﻚ واﺣﺪ أو أﻛﺜﺮ ﻣﻦ اﻷﻣﺮاض اﻟﺘﺎﻟﯿﺔ :</p><p>-اﻷﻣﺮاض اﻟﻤﻨﺎﻋﯿﺔ اﻟﺸﺪﯾﺪة ﻣﺜﻞ ﻋﺪوى ﻓﯿﺮوس ﻧﻘﺺ اﻟﻤﻨﺎﻋﺔ اﻟﺒﺸﺮﯾﺔ، واﻟﺘﺼﻠﺐ اﻟﻤﺘﻌﺪد (&nbsp;MS)أو &nbsp; اﻟﺬﺋﺒﺔ اﻟﺤﻤﺎﻣﯿﺔ ( LE) او&nbsp;&nbsp;اﻋﺘﻼل ﺑﯿﻀﺎء اﻟﺪﻣﺎغ ﻣﺘﻌﺪد اﻟﺒﺆر اﻟﺘﻘﺪﻣﯿﺔ (PML)&nbsp;</p><p>-اﻷﻣﺮاض اﻟﻤﻌﺪﯾﺔ اﻟﺤﺎدة واﻟﺸﺪﯾﺪة ﻣﺜﻞ اﻟﺴﻞ، أو اﻟﺘﮭﺎب اﻟﻜﺒﺪ اﻟﺤﺎد &nbsp;</p><p>-اﻟﺴﺮطﺎن ﺑﺎﺳﺘﺜﻨﺎء( ﺳﺮطﺎن اﻟﺨﻼﯾﺎ اﻟﻘﺎﻋﺪﯾﺔ، وھﻮ ﻧﻮع ﺑﻄﻲء اﻟﻨﻤﻮ ﻣﻦ ﺳﺮطﺎن اﻟﺠﻠﺪ)</p><p>&nbsp; -أو ﺿﻌﻒ ﺷﺪﯾﺪ ﻓﻲ وظﺎﺋﻒ اﻟﻘﻠﺐ</p><p>ھﻨﺎك ﻧﻘﺺاﻟﺨﺒﺮة ذات اﻟﺼﻠﺔ ﻣﻊ روﻓﻼﺳﺖ ﻓﻲ ظﻞ ھﺬه اﻟﻈﺮوف ,&nbsp;ﯾﺠﺐ ﻋﻠﯿﻚ اﻟﺘﺤﺪث ﻣﻊ طﺒﯿﺒﻚ إذا ﺗﻢ ﺗﺸﺨﯿﺺك ﺑﺄي ﻣﻦ ھﺬه اﻷﻣﺮاض.</p><p>اﻟﺘﺠﺮﺑﺔ أﯾﻀﺎ ﻣﺤﺪودة ﻓﻲ اﻟﻤﺮﺿﻰ اﻟﺬﯾﻦ ﺗﻢ ﺗﺸﺨﯿﺺھﻢ ﺳﺎﺑقا &nbsp;باﻟﺴﻞ، أواﻟﺘﮭﺎب اﻟﻜﺒﺪ اﻟﻔﯿﺮوﺳﻲ، أواﻟﮭﺮﺑﺲ و ھﻮﻋﺪوى ﻓﯿﺮوﺳﯿﺔ أو اﻟﺤﻸ اﻟﻨﻄﺎﻗﻲ</p><p>ﯾﺮﺟﻰ اﻟﺘﺤﺪث ﻣﻊ طﺒﯿﺒﻚ إذا ﻛﺎن ﻟﺪﯾﻚ واﺣﺪ ﻣﻦ ھﺬه اﻷﻣﺮاض.</p><p><strong>اﻷﻋﺮاض ﯾﺠﺐ أن ﺗﻜﻮن ﻋﻠﻰ ﻋﻠﻢ ﺑﮭﺎ</strong></p><p>ﻗﺪ ﯾﺤﺪث ﻟﻚ اﻹﺳﮭﺎل، اﻟﻐﺜﯿﺎن، أﻟﻢ ﻓﻲ اﻟﺒﻄﻦ أو اﻟﺼﺪاع ﺧﻼل اﻷﺳﺎﺑﯿﻊ اﻷوﻟﻰ ﻣﻦ اﻟﻌﻼج ب روفلاست&nbsp;,&nbsp;ﺗﺤﺪث ﻣﻊ طﺒﯿﺒﻚ إذا ﻛﺎﻧﺖ ھﺬه اﻷﻋﺮاض الﺟﺎﻧﺒﯿﺔ ﻻ ﺗﺰولﻓﻲ ﻏﻀﻮن اﻷﺳﺎﺑﯿﻊ اﻷوﻟﻰ ﻣﻦ اﻟﻌﻼج&nbsp;</p><p>ﻻ ﯾﻨﺼﺢ اﺳﺘﺨﺪام روﻓﻼﺳﺖ ﻓﻲ اﻟﻤﺮﺿﻰ اﻟﺬﯾﻦ ﻟﺪﯾﮭﻢ ﺗﺎرﯾﺦ ﻣﻦ اﻻﻛﺘﺌﺎب اﻟﻤﺮﺗﺒﻂ باﻟﺘﻔﻜﯿﺮ ﻓﻲ اﻻﻧﺘﺤﺎر أو اﻟﺴﻠﻮك اﻻﻧﺘﺤﺎري . ﻗﺪ ﯾﺤﺪث&nbsp; أﯾﻀﺎ اﻷرق، واﻟﻘﻠﻖ، واﻟﻌﺼﺒﯿﺔ، أو اﻟﻤﺰاج اﻻﻛﺘﺌﺎﺑﻲ . ﻗﺒﻞ ﺑﺪء اﻟﻌﻼج ﺑـ روﻓﻼﺳﺖ، إﺑﻠﻎ اﻟﻄﺒﯿﺐ إذا ﻛﻨﺖ ﺗﻌﺎﻧﻲ ﻣﻦ أي أﻋﺮاض ﻣﻦ ھﺬا اﻟﻨﻮع وأي أدوﯾﺔ إﺿﺎﻓﯿﺔ ﻗﺪ ﺗﺘﻨﺎوﻟﮭﺎ ﻷن ﺑﻌﺾ ﺗﻠﻚ اﻷدوﯾﺔ ﯾﻤﻜﻦ أن ﯾﺰﯾﺪ ﻣﻦ اﺣﺘﻤﺎل ھﺬه اﻷﻋﺮاض اﻟﺠﺎﻧﺒﯿﺔ .ﯾﺠﺐ ﻋﻠﯿﻚ أو ﻋﻠﻰ ﻣﻘﺪم اﻟﺮﻋﺎﯾﺔ اﻟﺨﺎص ﺑﻚ أﯾﻀﺎ أن ﺗﺒﻠﻎ طﺒﯿﺒﻚ ﻓﻮرا ﺑﺄي ﺗﻐﯿﺮات ﻓﻲ اﻟﺴﻠﻮك أو اﻟﻤﺰاج وعن أي أﻓﻜﺎر اﻧﺘﺤﺎرﯾﺔ ﻗﺪ ﺗﺤﺪث ﻟﻚ.</p><p>ا<strong>ﻷطﻔﺎل واﻟﻤﺮاھﻘﯿﻦ&nbsp; 18</strong></p><p>ﻻ ﯾﺠﺐ اﺳﺘﺨﺪام روﻓﻼﺳﺖ ﻣﻦ ﻗﺒﻞ اﻷطﻔﺎل واﻟﻤﺮاھﻘﯿﻦ دون ﺳﻦ&nbsp; 18 ﺳﻨﺔ ﻣﻦ اﻟﻌﻤﺮ</p><p><strong>اﻷدوﯾﺔ اﻷﺧﺮى و روﻓﻼﺳﺖ</strong></p><p>&nbsp;أﺧﺒﺮ طﺒﯿﺒﻚ أو اﻟﺼﯿﺪﻟﻲ إذا ﻛﻨﺖ ﺗﺘﻨﺎول، ﻗﺪ ﺗﻨﺎوﻟﺖ ﻣﺆﺧﺮا أو ﻗﺪ ﺗﺘﻨﺎول أي أدوﯾﺔ أﺧﺮى وﺧﺎﺻﺔ ﻣﺎ ﯾﻠﻲ</p><p>&nbsp;-دواء&nbsp; يحتوي&nbsp; ﻋﻠﻰ ﺛﯿﻮﻓﯿﻠﯿﻦ (دواء ﻟﻌﻼج أﻣﺮاض اﻟﺠﮭﺎز اﻟﺘﻨﻔﺴﻲ)</p><p>&nbsp;-دواء ﯾﺴﺘﺨﺪم ﻟﻌﻼج اﻷﻣﺮاض اﻟﻤﻨﺎﻋﯿﺔ، ﻣﺜﻞ ﻣﯿﺜﻮﺗﺮﯾﻜﺴﺎت، آزوﺛﯿﻮﺑﺮﯾﻦ إﯾﻨﻔﻠﯿﻜﺴﯿﻢاب، إﯾﺗﺎﻧﯾرﺳﺑت ، أو ﻛﻮرﺗﯿﺰون ﻋﻦ طﺮﯾﻖ اﻟﻔﻢ اﻟﺘﻲ ﯾﺘﻌﯿﻦ ﺗﻨﺎوﻟﮭﺎ ﻋﻠﻰ اﻟﻤﺪى اﻟﻄﻮﯾﻞ &nbsp;،</p><p>-دواء يحتوي&nbsp;ﻋﻠﻰ ﻓﻠﻮﻓﻮﻛﺴﺎﻣﯿﻦ (دواء ﻟﻌﻼج اﺿﻄﺮاﺑﺎت اﻟﻘﻠﻖ واﻻﻛﺘﺌﺎب)ا, إﯾﻧوﻛزاﺳﯾن (دواء ﻟﻌﻼج اﻻﻟﺘﮭﺎﺑﺎت اﻟﺒﻜﺘﯿﺮﯾﺔ)أو ﺳﯿﻤﯿﺘﯿﺪﯾﻦ ( دواء ﻟﻌﻼج ﻗﺮﺣﺔ اﻟﻤﻌﺪة أو اﻟﺤﻤﻮﺿﮫ اﻟمعوية).</p><p>&nbsp;رﺑﻤﺎ ﯾﺘﻢ ﺧﻔﺾ ﺗﺄﺛﯿﺮ روﻓﻼﺳﺖ إذا ﺗﻢ ﺗﻨﺎوﻟﮫ&nbsp;ﻣﻊ رﯾﻔﺎﻣﺒﯿﺴﯿﻦ (دواء ﻣﻀﺎد ﺣﯿﻮي) أو ﻣﻊ ﻓﯿﻨﻮﺑﺎرﺑﯿﺘﺎل أو ﻛﺎرﺑﺎﻣﺎزﯾﺑﯾن أو ﻓﯾﻧﯾﺗوﯾن(اﻷدوﯾﺔ اﻟﻤﻮﺻﻮﻓﺔ ﻋﺎدة ﻟﻌﻼج اﻟﺼﺮع )</p><p>إﺳﺄل طﺒﯿﺒﻚ ﻟﻠﺤﺼﻮل ﻋﻠﻰ اﻟﻤﺸﻮرة</p><p>ﯾﻤﻜﻦ أن ﯾﺘﻢ ﺗﻨﺎول روﻓﻼﺳﺖ ﻣﻊ اﻷدوﯾﺔ اﻷﺧﺮى اﻟﻤﺴﺘﺨﺪﻣﺔ ﻓﻲ ﻋﻼج ﻣﺮض اﻻﻧﺴﺪاد اﻟﺮﺋﻮي اﻟﻤﺰﻣﻦ ﻣﺜﻞ اﻟﺴﺘﯿﺮوﯾﺪات اﻟﻤﺴﺘﻨﺸﻘﺔ أو اﻟﺘﻰ ﯾﺘﻢ ﺗﻨﺎوﻟﮭﺎ ﻋﻦ طﺮﯾﻖ اﻟﻔﻢ أو ﻣﻮﺳﻌﺎت اﻟﺸﻌﺐ اﻟﮭﻮاﺋﯿﺔ . ﻻ ﺗﺘﻮﻗﻒ ﻋﻦ ﺗﻨﺎول ھﺬه اﻷدوﯾﺔ أو ﺗﻘﻠﯿﻞ اﻟﺠﺮﻋﺔ &nbsp;ﻣﺎ ﻟﻢ ﯾﻨﺼﺢ اﻟﻄﺒﯿﺐ.</p><p><strong>اﻟﺤﻤﻞ واﻟﺮﺿﺎﻋﺔ اﻟﻄﺒﯿﻌﯿﺔ&nbsp;</strong></p><p>ﻻ ﺗﺘﻨﺎولي روﻓﻼﺳﺖ إذا ﻛﻨﺖي ﺣﺎﻣﻼ أو ﺗﺨﻄﻄﯿﻦ ﻟﺘﺼﺒﺤﻲ ﺣﺎﻣﻼ، أو تﻋﺘﻘﺪﯾﻦ أﻧﻚ ﻗﺪ ﺗﻜﻮني ﺣﺎﻣﻼ، أو ﺗﻘﻮﻣﯿﻦ ﺑﺎﻟﺮﺿﺎﻋﺔ اﻟﻄﺒﯿﻌﯿﺔ ﯾﺠﺐ أن ﻻ ﺗصبحي&nbsp;ﺣﺎﻣﻼ أﺛﻨﺎء ﺗﻨﺎول ھﺬا اﻟﺪواء وﯾﺠﺐ اﺳﺘﺨﺪام وﺳﯿﻠﺔ ﻓﻌﺎﻟﺔ ﻟﻤﻨﻊ اﻟﺤﻤﻞ ﺧﻼل ﻓﺘﺮة اﻟﻌﻼج، ﻷن روﻓﻼﺳﺖ ﻗﺪ يكون&nbsp; ﺿﺎر ﻟﻠﻄﻔﻞ اﻟﺬي ﻟﻢ ﯾﻮﻟﺪ ﺑﻌﺪ</p><p><strong>اﻟﻘﯿﺎدة واﺳﺘﺨﺪام اﻵﻻت</strong></p><p>روﻓﻼﺳﺖ ﻟﯿﺲ ﻟﮫ أي ﺗﺄﺛﯿﺮ ﻋﻠﻰ اﻟﻘﺪرة ﻋﻠﻰ اﻟﻘﯿﺎدة واﺳﺘﺨﺪام اﻵﻻت.&nbsp;<br />&nbsp;<br /><strong>ﯾﺤﺘﻮي روﻓﻼﺳﺖ &nbsp;ﻋﻠﻰ ﻻﻛﺘﻮز </strong>إذا ﻗﯿﻞ ﻟﻚ ﻣﻦ ﻗﺒﻞ اﻟﻄﺒﯿﺐ أن ﻟﺪﯾﻚ ﻋﺪم ﺗﺤﻤﻞ ﻟﺒﻌﺾ اﻟﺴﻜﺮﯾﺎت، اﺗﺼﻞ اﻟﻄﺒﯿﺐ ﻗﺒﻞ ﺗﻨﺎول ھﺬا اﻟﺪواء&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>داﺋﻤﺎ ﺗﻨﺎول ھﺬا اﻟﺪواء ﺗﻤﺎﻣﺎ ﻛﻤﺎ أﺧﺒﺮك &nbsp;طﺒﯿﺒﻚ .اﺳﺘﺸﺮ طﺒﯿﺒﻚ أو اﻟﺼﯿﺪﻟﻲ إذا ﻟﻢ ﺗﻜﻦ ﻣﺘﺄﻛﺪا .</p><p>اﻟﺠﺮﻋﺔ اﻟﻤﻮﺻﻰ ﺑﮭﺎ ھﻲ ﻗﺮص واﺣﺪ 500 ﻣﯿﻜﺮوجرام ﻣﺮة واﺣﺪة ﯾﻮﻣﯿﺎ</p><p>اﺑﺘﻠﻊ القرص&nbsp;&nbsp;ﻣﻊ ﺑﻌﺾ اﻟﻤﺎء .يمكنك ان ﺗﺘﻨﺎول ھﺬا اﻟﺪواء ﻣﻊ أو ﺑﺪون اﻟﻄﻌﺎم .</p><p>ﯾﺆﺧﺬ اﻟﻘﺮص ﻓﻲ ﻧﻔﺲ اﻟﻮﻗﺖ ﻛﻞ ﯾﻮم.</p><p>ﻗﺪ ﺗﺤﺘﺎج إﻟﻰ ﺗﻨﺎول روﻓﻼﺳﺖ ﻟﻌﺪة أﺳﺎﺑﯿﻊ ﻟﺘﺤﻘﯿﻖ ﺗﺄﺛﯿﺮه اﻟﻤﻔﯿﺪ&nbsp;<br />&nbsp;<br /><strong>إذا ﺗﺘﻨﺎوﻟﺖ روﻓﻼﺳﺖ أﻛﺜﺮ ﻣﻤﺎ ﯾﺠﺐ</strong></p><p>إذا ﻛﻨﺖ ﻗﺪ ﺗﻨﺎوﻟﺖ ﻣﺰﯾﺪا ﻣﻦ اﻷﻗﺮاص أﻛﺜﺮ ﻣﻤﺎ ﯾﺠﺐ ﻗﺪ تتعرض&nbsp; ﻷﻋﺮاض اﻟﺘﺎﻟﯿﺔ :&nbsp;&nbsp;اﻟﺼﺪاع، اﻟﻐﺜﯿﺎن، اﻹﺳﮭﺎل، اﻟﺪوار,&nbsp;&nbsp;وﺧﻔﻘﺎن ﻗﻠﺒﻚ، اﻟﺪوار اﻟﺨﻔﯿﻒ, اﻟﻠﺰوﺟﺔ، واﻧﺨﻔﺎض ﺿﻐﻂ اﻟﺪم .&nbsp; أﺧﺒﺮ طﺒﯿﺒﻚ أو اﻟﺼﯿﺪﻟﻲ ﻓﻮرا .إذا ﻛﺎن ذﻟﻚ ﻣﻤﻜﻨﺎ ﺧﺬ اﻟﺪواء وھﺬه اﻟﻨﺸﺮة ﻣﻌﻚ.&nbsp;<br />&nbsp;<br /><strong>إذا ﻛﻨﺖ ﻗﺪ ﻧﺴﯿﺖ أن ﺗﺘﻨﺎول روﻓﻼﺳﺖ</strong> إذا ﻛﻨﺖ ﻗﺪ ﻧﺴﯿﺖ أن ﺗﺘﻨﺎول القرص&nbsp;ﻓﻲ اﻟﻮﻗﺖ اﻟﻤﻌﺘﺎد، ﺗﻨﺎول الﻗﺮص ﺑﻤﺠﺮد التذكر&nbsp;ﻧﻔﺲ اﻟﯿﻮم . اذا نسيت ان ﺗﺘﻨﺎول ﻗﺮص ﻣﻦ روﻓﻼﺳﺖ ﻓﻲ ﯾﻮم ﻣﺎ، ﻓﻘﻂ ﺗﻨﺎول القرص القادم ﻓﻲ اﻟﯿﻮم اﻟﺘﺎﻟﻲ ﻛﺎﻟﻤﻌﺘﺎد .استمر في ﺗﻨﺎول&nbsp;اﻟﺪواء ﻓﻲ اﻷوﻗﺎت اﻟﻤﻌﺘﺎدة . لا ﺗﺘﻨﺎول ﺟﺮﻋﺔ ﻣﻀﺎﻋﻔﺔ ﻟﺘﻌﻮﯾﺾ اﻟﺠﺮﻋﺔ اﻟﻤﻨﺴﯿﺔ.&nbsp;<br />&nbsp;<br /><strong>إذا ﺗﻮﻗﻔﺖ ﻋﻦ ﺗﻨﺎول روﻓﻼﺳﺖ</strong></p><p>ﻣﻦ اﻟﻀﺮورى ﻣﻮاﺻﻠﺔ ﺗﻨﺎول روﻓﻼﺳﺖ طﺎﻟﻤﺎ وﺻﻔﮫ طﺒﯿﺒﻚ، ﺣﺘﻰ ﻋﻨﺪﻣﺎ ﻻ ﯾﻜﻮن ﻟﺪﯾﻚ أي أﻋﺮاض، ﻣﻦ أﺟﻞ اﻟﺤﻔﺎظ ﻋﻠﻰ اﻟﺴﯿﻄﺮة ﻋﻠﻰ وظﯿﻔﺔ اﻟﺮﺋﺔ.</p><p>إذا ﻛﺎن ﻟﺪﯾﻚ أي أﺳﺌﻠﺔ أﺧﺮى ﻋﻦ اﺳﺘﺨﺪام ھﺬا اﻟﺪواء، إﺳﺄل طﺒﯿﺒﻚ أو اﻟﺼﯿﺪﻟﻲ.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>ﻣﺜﻞ ﺟﻤﯿﻊ اﻷدوﯾﺔ، ﯾﻤﻜﻦ ﻟﮭﺬا اﻟﺪواء أن ﯾﺴﺒﺐ أﻋﺮاض ﺟﺎﻧﺒﯿﺔ، ﻋﻠﻰ اﻟﺮﻏﻢ ﻣﻦ أنھﺎ ﻻ ﺗﺤﺪث للجميع.&nbsp;&nbsp;<br />&nbsp;<br />&nbsp;<br />ﻗﺪ تتعرض ﻟـ&nbsp; اﻹﺳﮭﺎل واﻟﻐﺜﯿﺎن وآﻻم اﻟﻤﻌﺪة أو اﻟﺼﺪاع ﺧﻼل اﻷﺳﺎﺑﯿﻊ اﻷوﻟﻰ ﻣﻦ اﻟﻌﻼج ﻣﻊ روﻓﻼﺳﺖ . ﺗﺤﺪث إﻟﻰ طﺒﯿﺒﻚ إذا&nbsp; ﻛﺎﻧﺖ ھﺬه اﻷﻋﺮاض الﺟﺎﻧﺒﯿﺔ ﻻ ﺗﺰول&nbsp;&nbsp;ﻓﻲ ﻏﻀﻮن اﻷﺳﺎﺑﯿﻊ اﻷوﻟﻰ ﻣﻦ اﻟﻌﻼج.</p><p>ﺑﻌﺾ اﻷﻋﺮاض اﻟﺠﺎﻧﺒﯿﺔ ﯾﻤﻜﻦ أن ﺗﻜﻮن ﺧﻄﯿﺮة .ﻓﻲ اﻟﺪراﺳﺎت اﻟﺴﺮﯾﺮﯾﺔ وﺗﺠﺮﺑﺔ ﻣﺎ ﺑﻌﺪ اﻟﺘﺴﻮﯾﻖ، ﺗﻢ اﻹﺑﻼغ ﻋﻦ ﺣﺎﻻت ﻧﺎدرة ﻣﻦ اﻟﺘﻔﻜﯿﺮ ﻓﻲ اﻻﻧﺘﺤﺎر واﻟﺴﻠﻮك اﻻﻧﺘﺤﺎري( ﺑﻤﺎ ﻓﻲ ذﻟﻚ اﻻﻧﺘﺤﺎر) اﻟﺮﺟﺎء إﺑﻼغ اﻟﻄﺒﯿﺐ ﻋﻠﻰ اﻟﻔﻮر ﻋﻦ أي أﻓﻜﺎر انتحارية قد تكون لديكم . قد تواجه ايضا عدم القدرة على النوم ( شائع), والقلق (غير شائع) , والعصبية ( نادر ) , نوبات الذعر ( نادر ) , او المزاج الاكتئابي ( نادر )&nbsp;</p><p>وﻓﻲ ﺣﺎﻻت ﻏﯿﺮ ﺷﺎئعة &nbsp;ﻗﺪ ﺗﺤﺪث ﺗﻔﺎﻋﻼت اﻟﺤﺴﺎﺳﯿﺔ . ﻗﺪ ﺗﺆﺛﺮ ﺗﻔﺎﻋﻼت اﻟﺤﺴﺎﺳﯿﺔ ﻋﻠﻰ اﻟﺠﻠﺪ وﻓﻲ ﺣﺎﻻت ﻧﺎدرة ﯾﺴﺒﺐ ﺗﻮرم ﻓﻲ اﻟﺠﻔﻮن واﻟﻮﺟﮫ واﻟﺸﻔﺘﯿﻦ واﻟﻠﺴﺎن، ﻣﻤﺎ ﻗﺪ ﯾﺆدي إﻟﻰ ﺻﻌﻮﺑﺎت ﻓﻲ اﻟﺘﻨﻔﺲ و &nbsp;/أو اﻧﺨﻔﺎض ﻓﻲ ﺿﻐﻂ اﻟﺪم وﺗﺴﺎرع ﺿﺮﺑﺎت اﻟﻘﻠﺐ .ﻓﻲ ﺣﺎﻟﺔ وﺟﻮد رد ﻓﻌﻞ ﺗﺤﺴﺴﻲ، ﺗﻮﻗﻒ ﻋﻦ ﺗﻨﺎول روﻓﻼﺳﺖ واﺗﺼﻞ ﺑﻄﺒﯿﺒﻚ ﻓﻮرا، أو اذھﺐ ﻣﺒﺎﺷﺮة إﻟﻰ ﻗﺴﻢ اﻟﻄﻮارئ ﻓﻲ أﻗﺮب ﻣﺴﺘﺸﻔﻰ .ﺧﺬ ﺟﻤﯿﻊ اﻷدوﯾﺔ اﻟﺨﺎﺻﺔ ﺑﻚ وھﺬه اﻟﻨﺸﺮة ﻣﻌﻚ و . ﻗﺪم ﻣﻌﻠﻮﻣﺎت ﻛﺎﻣﻠﺔ ﻋﻦ اﻷدوﯾﺔ الحالية .&nbsp;</p><p>وﺗﺸﻤﻞ اﻷﻋﺮاض اﻟﺠﺎﻧﺒﯿﺔ اﻷﺧﺮى ﻣﺎ ﯾﻠﻲ :</p><p>أﻋﺮاضﺟﺎﻧﺒﯿﺔ ﺷﺎﺋﻌﺔ( ﻗﺪ تؤﺛﺮ ﻋﻠﻰ ﻣﺎ ﯾﺼﻞ إﻟﻰ&nbsp; 1في 10 اشخاص )</p><p>&nbsp;-اﻹﺳﮭﺎل، اﻟﻐﺜﯿﺎن، آﻻم اﻟﻤﻌﺪة &nbsp;</p><p>-ﻧﻘﺼﺎن اﻟﻮزن، ﻗﻠﺔ اﻟﺸﮭﯿﺔ</p><p>&nbsp;-الصداع&nbsp;</p><p>أﻋﺮاض ﺟﺎﻧﺒﯿﺔ ﻏﯿﺮ ﺷﺎﺋﻌﺔ (ﻗﺪ تؤﺛﺮ ﻋﻠﻰ ﻣﺎ ﯾﺼﻞ إﻟﻰ 1 في 100 شخص )</p><p>&nbsp;&nbsp;-اﻻرﺗﺠﺎف، واﻹﺣﺴﺎس بدوران اﻟﺮأس ( الدوار)&nbsp; ، واﻟﺪوﺧﺔ&nbsp; -اﻹﺣﺴﺎس وﺳﺮﻋﺔ أو ﻋﺪم اﻧﺘﻈﺎم&nbsp; ﺿﺮﺑﺎت اﻟﻘﻠﺐ(ﺧﻔﻘﺎن)&nbsp; -اﻟﺘﮭﺎب اﻟﻤﻌﺪة واﻟﻘﻲء</p><p>&nbsp;-ارتﺟﺎع ﺣﻤﺾ اﻟﻤﻌﺪة إﻟﻰ اﻟﻤﺮيء (ارﺗﺠﺎع&nbsp; الحامض ) ، وﻋﺴﺮ اﻟﮭﻀﻢ&nbsp;</p><p>&nbsp;-طﻔﺢ ﺟﻠﺪي</p><p>&nbsp;-آﻻم ﻓﻲ اﻟﻌﻀﻼت، وﺿﻌﻒ اﻟﻌﻀﻼت أو ﺗﺸﻨﺠﺎت</p><p>-أﻟﻢ ﻓﻲ اﻟﻈﮭﺮ &nbsp;</p><p>-اﻟﺸﻌﻮر ﺑﺎﻟﻀﻌﻒ أو اﻟﺘﻌﺐ، واﻟﺸﻌﻮر ﺑﺎﻹﻋﯿﺎء.</p><p>أﻋﺮاض ﺟﺎﻧﺒﯿﺔ ﻧﺎدرة (ﻗﺪ تؤﺛﺮ ﻋﻠﻰ ﻣﺎ ﯾﺼﻞ إﻟﻰ 1 في 1000&nbsp; &nbsp;ﺷﺨﺺ)&nbsp;</p><p>-ﻛﺒﺮ اﻟﺜﺪي ﻋﻨﺪ اﻟﺮﺟﺎل</p><p>&nbsp;-اﻧﺨﻔﺎض ﺣﺎﺳﺔ اﻟﺘﺬوق</p><p>&nbsp;-اﻟﺘﮭﺎﺑﺎت اﻟﺠﮭﺎز اﻟﺘﻨﻔﺴﻲ(ﺑﺎﺳﺘﺜﻨﺎء اﻻﻟﺘﮭﺎب اﻟﺮﺋﻮي)</p><p>&nbsp;-ظﮭﻮر اﻟﺪم ﻓﻲ اﻟﺒﺮاز، واﻹﻣﺴﺎك</p><p>&nbsp;-ارﺗﻔﺎع أﻧﺰﯾﻤﺎت اﻟﻜﺒﺪ أو اﻟﻌﻀﻼت( ﯾﺮى ﻓﻲ اﺧﺘﺒﺎرات اﻟﺪم )</p><p>-اﻟﺸﺮوي(اﻷرﺗﯿﻜﺎرﯾﺎ) .</p><p><strong>اﻹﺑﻼغ ﻋﻦ اﻷﻋﺮاض الجانبية&nbsp;</strong>&nbsp;اذا ﻛﺎن ﻟﺪﯾﻚ أي أﻋﺮاض ﺟﺎﻧﺒﯿﺔ، ﺗﺤﺪث ﻣﻊ طﺒﯿﺒﻚ أو اﻟﺼﯿﺪﻟﻲ .وﯾﺸﻤﻞ ذﻟﻚ أي أﻋﺮاض ﺟﺎﻧﺒﯿﺔ ﻣﺤﺘﻤﻠﺔ ﻏﯿﺮ ﻣﺪرﺟﺔ ﻓﻲ ھﺬه اﻟﻨﺸﺮة .ﯾﻤﻜﻨﻚ أﯾﻀﺎ اﻹﺑﻼغ ﻋﻦ اﻷﻋﺮاض الجانبية المباشرة (اﻧﻈﺮ اﻟﺘﻔﺎﺻﯿﻞ أدﻧﺎه). من خلال اﻹﺑﻼغ ﻋﻦ اﻷﻋﺮاض الﺟﺎﻧﺒﯿﺔ ﯾﻤﻜﻦ أن ﺗﺴﺎﻋﺪ ﻓﻲ ﺗﻮﻓﯿﺮ ﻣﺰﯾﺪ ﻣﻦ اﻟﻤﻌﻠﻮﻣﺎت ﺣﻮل ﺳﻼﻣﺔ ھﺬا اﻟﺪواء.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>ﯾﺤﻔﻆ اﻟﺪواء ﻓﻰ درﺟﺔ ﺣﺮارة ﻻ ﺗﺰﯾﺪ ﻋﻦ 30 درﺟﺔ ﻣﺌﻮﯾﺔﺑﻌﯿﺪا يحفظ الدواء ﻋﻦ بعيدا عن ﻣﺘﻨﺎول وﻧﻈﺮ اﻷطﻔﺎل.</p><p>ﻻ ﺗﺴﺘﻌﻤﻞ ھﺬا اﻟﺪواء ﺑﻌﺪ اﻧﺘﮭﺎء ﺗﺎرﯾﺦ اﻟﺼﻼﺣﯿﺔ اﻟﻤﺪون ﻋﻠﻰ اﻟﻌﺒﻮة و اﻟﺸﺮﯾﻂ ﺑﻌﺪ ﻛﻠﻤﺔ EXP</p><p>ﯾﺸﯿﺮ ﺗﺎرﯾﺦ اﻟﺼﻼﺣﯿﺔ إﻟﻰ آﺧﺮ ﯾﻮم ﻓﻲ اﻟﺸﮭﺮ .</p><p>ﻻ ﺗﺘﺨﻠﺺ ﻣﻦ أي أدوﯾﺔ ﻋﻦ طﺮﯾﻖ ﻣﯿﺎه اﻟﺼﺮف اﻟﺼﺤﻲ أو اﻟﻨﻔﺎﯾﺎت اﻟﻤﻨﺰﻟﯿﺔ .اﺳﺄل اﻟﺼﯿﺪﻟﻲ ﻛﯿﻔﯿﺔ رﻣﻲ اﻷدوﯾﺔ اﻟﺘﻲ ﻟﻢ ﺗﻌﺪ ﺗﺴﺘﺨﺪم ﺑﻌﯿﺪا .وﻣﻦ ﺷﺄن ھﺬه اﻟﺘﺪاﺑﯿﺮ أن ﺗﺴﺎﻋﺪ ﻓﻲ ﺣﻤﺎﯾﺔ اﻟﺒﯿﺌﺔ&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>-اﻟﻤﺎدة اﻟﻔﻌﺎﻟﺔ ﻓﻲ روﻓﻼﺳﺖ ھﻲ روﻓﻠﻮﻣﯿﻼﺳﺖ ﯾﺤﺘﻮي ﻛﻞ ﻗﺮص ﻣﻐﻠﻒ ﺑﻄﺒﻘﺔ رﻗﯿﻘﺔ ﻋﻠﻰ &nbsp; 500 ﻣﯿﻜﺮوﺟﺮام. ﻣﻦ روﻓﻠﻮﻣﯿﻼﺳﺖ.</p><p>&nbsp;-اﻟﻤﻜﻮﻧﺎت اﻷﺧﺮى ھﻰ :</p><p>-ﻟﺐ اﻟﻘﺮص :ﻻﻛﺘﻮز ﺑﻲ ﺑﻲ200و ﻧﺸﺎ ذرة و ﺑﻮﻓﯿﺪون&nbsp;30 &nbsp;و ﺳﺘﯿﺎرﯾﺖ اﻟﻤﺎﻏﻨﺴﯿﻮم</p><p>-ﻏﻼف اﻟﻘﺮص :ھﯿﺪروﻛﺴﻲ ﺑﺮوﺑﺎﯾﻞ ﻣﯿﺜﯿﻞ ﺳﯿﻠﻠﯿﻠﻮز و ﺗﯿﺘﺎﻧﯿﻮم ﺛﻨﺎﺋﻲ اﻟﺘﺄﻛﺴﺪ ﻓﺎرﻣﺎ ﺟﺮﯾﺪ و ﺑﻮﻟﻲ إﯾﺜﯿﻠﯿﻦ ﺟﻠﯿﻜﻮل إم دﺑﻠﯿﻮ 6000. و ﺗﻠﻚ ﻣﻨﻘﻰ و ﺣﺪﯾﺪ أوﻛﺴﯿﺪ أﺻﻔﺮ و ﻣﺎء ﻣﻨﻘﻰ ﺑﻲ ﺑﻲ &nbsp;</p><p>. ﯾﺤﺘﻮي ﻛﻞ ﻗﺮص ﻣﻐﻠﻒ ﺑﻄﺒﻘﺔ رﻗﯿﻘﺔ ﻣﻦ روﻓﻼﺳﺖ 500&nbsp;ﻣﯿﻜﺮوﺟﺮام على 500 ﻣﯿﻜﺮوﺟﺮام من روﻓﻠﻮﻣﯿﻼﺳﺖ &nbsp;&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>ﺷﻜﻞ روﻓﻼﺳﺖ وﻣﻜﻮﻧﺎت اﻟﻌﺒﻮة</p><p>قرص روفالست 500 ميكروجرام المغلف&nbsp;بطبقة رقيقة هو قرص أصفر فاتح إلى أصفر، مستدير، محدب الوجهين ، مغلف بطبقة رقيقة ، محفور 241 عىل أحد السطحين و عادي على&nbsp;&nbsp;السطح الاخر</p><p>&nbsp;</p><p>تحتوي كل عبوة من روفالست عىل 30 قرص مغلف بطبقة رقيقة</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>ﺻﻨﻊ ﺑﻮاﺳﻄﺔ :</p><p><strong>اﻟﺪواﺋﯿﺔ</strong></p><p>ﻣﺼﻨﻊ اﻷدوﯾﺔ ﺑﺎﻟﻘﺼﯿﻢ</p><p>اﻟﻤﻤﻠﻜﺔ اﻟﻌﺮﺑﯿﺔ اﻟﺴﻌﻮدﯾﺔ&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            ﺗﻢ اﻟﻤﻮاﻓﻘﺔ ﻋﻠﻰ ھﺬه اﻟﻨﺸﺮة ﺑﺘﺎرﯾﺦ ﻓﺒﺮاﯾﺮ  2017
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Roflast 500 micrograms film-coated tablets 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet contains 500 micrograms of roflumilast. 
 
Excipient with known effect: Each film-coated tablet contains 190.750 mg lactose BP 200. For the full list of excipients, see section 6.1. 
 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet (tablet). 
 
Light yellow to yellow coloured, round, biconvex film-coated tablet, engraved with “241” on one side and plain on the other side
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Roflast is indicated for maintenance treatment of severe chronic obstructive pulmonary disease (COPD) (FEV1 post-bronchodilator less than 50% predicted) associated with chronic bronchitis in adult patients with a history of frequent exacerbations as add on to bronchodilator treatment.&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology The recommended dose is 500 micrograms (one tablet) roflumilast once daily. Roflast may need to be taken for several weeks to achieve its effect (see section 5.1). Roflast has been studied in clinical trials for up to one year.&nbsp;<br />&nbsp;<br />Special populations Elderly No dose adjustment is necessary. Renal impairment No dose adjustment is necessary. Hepatic impairment&nbsp;</p><p>&nbsp;</p><p>The clinical data with Roflast in patients with mild hepatic impairment classified as ChildPugh A are insufficient to recommend a dose adjustment (see section 5.2) and therefore Roflast should be used with caution in these patients.&nbsp;<br />&nbsp;<br />Patients with moderate or severe hepatic impairment classified as Child-Pugh B or C must not take Roflast (see section 4.3).&nbsp;<br />&nbsp;<br />Paediatric population There is no relevant use of Roflast in the paediatric population (under 18 years) in the indication COPD.&nbsp;<br />&nbsp;<br />Method of administration For oral use. The tablet should be swallowed with water and taken at the same time every day. The tablet can be taken with or without food.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Moderate or severe hepatic impairment (Child-Pugh B or C). 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>All patients should be informed about the risks of Roflast and the precautions for safe use and should be given a patient card before starting Roflast.&nbsp;<br />&nbsp;<br />Rescue medicinal products Roflast is not indicated as rescue medicinal product for the relief of acute bronchospasms.&nbsp;<br />&nbsp;<br />Weight decrease In 1-year studies (M2-124, M2-125), a decrease of body weight occurred more frequently in patients treated with roflumilast compared to placebo-treated patients. After discontinuation of roflumilast, the majority of patients had regained body weight after 3 months.&nbsp;<br />&nbsp;<br />Body weight of underweight patients should be checked at each visit. Patients should be advised to check their body weight on a regular basis. In the event of an unexplained and clinically concerning weight decrease, the intake of roflumilast should be stopped and body weight should be further followed-up.&nbsp;<br />&nbsp;<br />Special clinical conditions Due to lack of relevant experience, treatment with roflumilast should not be initiated or existing treatment with roflumilast should be stopped in patients with severe immunological diseases (e.g. HIV infection, multiple sclerosis, lupus erythematosus, progressive multifocal leukoencephalopathy), severe acute infectious diseases, cancers (except basal cell carcinoma),&nbsp;</p><p>or patients being treated with immunosuppressive medicinal products (i.e.: methotrexate, azathioprine, infliximab, etanercept, or oral corticosteroids to be taken long-term; except shortterm systemic corticosteroids). Experience in patients with latent infections such as tuberculosis, viral hepatitis, herpes viral infection and herpes zoster is limited.&nbsp;<br />&nbsp;<br />Patients with congestive heart failure (NYHA grades 3 and 4) have not been studied and therefore treatment of these patients is not recommended.&nbsp;<br />&nbsp;<br />Psychiatric disorders Roflumilast is associated with an increased risk of psychiatric disorders such as insomnia, anxiety, nervousness and depression. Rare instances of suicidal ideation and behaviour, including suicide, have been observed in patients with or without history of depression, usually within the first weeks of treatment (see section 4.8). The risks and benefits of starting or continuing treatment with roflumilast should be carefully assessed if patients report previous or existing psychiatric symptoms or if concomitant treatment with other medicinal products likely to cause psychiatric events is intended.&nbsp;<br />&nbsp;<br />Roflumilast is not recommended in patients with a history of depression associated with suicidal ideation or behaviour. Patients and caregivers should be instructed to notify the prescriber of any changes in behaviour or mood and of any suicidal ideation. If patients suffered from new or worsening psychiatric symptoms, or suicidal ideation or suicidal attempt is identified, it is recommended to discontinue treatment with roflumilast.&nbsp;<br />&nbsp;<br />Persistent intolerability While adverse reactions like diarrhoea, nausea, abdominal pain and headache mainly occur within the first weeks of therapy and mostly resolve on continued treatment, roflumilast treatment should be reassessed in case of persistent intolerability. This might be the case in special populations that may have higher exposure, such as in black, non-smoking females (see section 5.2) or in patients concomitantly treated with CYP1A2/ 2C19/3A4 inhibitors (such as fluvoxamine and cimetidine) or the CYP1A2/3A4 inhibitor enoxacin (see section 4.5).&nbsp;<br />&nbsp;<br />Body weight &lt;60 kg Treatment with roflumilast may lead to a higher risk of sleep disorders (mainly insomnia) in patients with a baseline body weight of &lt;60 kg, due to a higher total PDE4 inhibitory activity found in these patients (see section 4.8).&nbsp;<br />&nbsp;<br />Theophylline There are no clinical data to support the concomitant treatment with theophylline for maintenance therapy. Therefore, the concomitant treatment with theophylline is not recommended.&nbsp;<br />&nbsp;<br />Lactose Roflast tablets contain lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Interaction studies have only been performed in adults.&nbsp;<br />&nbsp;<br />A major step in roflumilast metabolism is the N-oxidation of roflumilast to roflumilast N-oxide by CYP3A4 and CYP1A2. Both roflumilast and roflumilast N-oxide have intrinsic phosphodiesterase-4 (PDE4) inhibitory activity. Therefore, following administration of roflumilast, the total PDE4 inhibition is considered to be the combined effect of both roflumilast and roflumilast N-oxide.&nbsp;<br />&nbsp;<br />Interaction studies with CYP1A2/3A4 inhibitor enoxacin and the CYP1A2/2C19/3A4 inhibitors cimetidine and fluvoxamine, resulted in increases of the total PDE4 inhibitory activity of 25%, 47% and 59%, respectively. The tested dose of fluvoxamine was 50 mg. A combination of roflumilast with these active substances might lead to an increase of exposure and persistent intolerability. In this case, roflumilast treatment should be reassessed (see section 4.4).&nbsp;<br />&nbsp;<br />Administration of the cytochrome P450 enzyme inducer rifampicin resulted in a reduction in total PDE4 inhibitory activity by about 60%. Therefore, the use of strong cytochrome P450 enzyme inducers (e.g. phenobarbital, carbamazepine, phenytoin) may reduce the therapeutic efficacy of roflumilast. Thus, roflumilast treatment is not recommended in patients receiving strong cytochrome P450 enzyme inducers.&nbsp;<br />&nbsp;<br />Clinical interaction studies with CYP3A4 inhibitors erythromycin and ketoconazole showed increases of 9% of the total PDE4 inhibitory activity. Co-administration with theophylline resulted in an increase of 8% of the total PDE4 inhibitory activity (see section 4.4). In an interaction study with an oral contraceptive containing gestodene and ethinyl oestradiol, the total PDE4 inhibitory activity was increased by 17%. No dose adjustment is necessary in patients receiving these active substances.&nbsp;<br />&nbsp;<br />No interactions were observed with inhaled salbutamol, formoterol, budesonide and oral montelukast, digoxin, warfarin, sildenafil and midazolam.&nbsp;<br />&nbsp;<br />Co-administration with an antacid (combination of aluminium hydroxide and magnesium hydroxide) did not alter the absorption or pharmacokinetics of roflumilast or its N-oxide.&nbsp;<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Women of childbearing potential Women of childbearing age should be advised to use an effective method of contraception during treatment. Roflumilast is not recommended in women of childbearing potential not using contraception.&nbsp;<br />&nbsp;<br />Pregnancy There are limited amount of data from the use of roflumilast in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). Roflumilast is not recommended during pregnancy. Roflumilast has been demonstrated to cross the placenta in pregnant rats.&nbsp;<br />&nbsp;<br />Breast-feeding Available pharmacokinetic data in animals have shown excretion of roflumilast or its metabolites in milk. A risk to the breastfed infant cannot be excluded. Roflumilast should not be used during breast-feeding.&nbsp;<br />&nbsp;<br />Fertility In a human spermatogenesis study, roflumilast 500 micrograms had no effects on semen parameters or reproductive hormones during the 3-month treatment period and the following 3month off-treatment period.&nbsp;&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Roflast has no influence on the ability to drive and use machines.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Summary of the safety profile In clinical COPD studies, approximately 16% of patients experienced adverse reactions with roflumilast (compared to 5% in placebo). The most commonly reported adverse reactions were diarrhoea (5.9%), weight decreased (3.4%), nausea (2.9%), abdominal pain (1.9%) and headache (1.7%). The majority of these adverse reactions were mild or moderate. These adverse reactions mainly occurred within the first weeks of therapy and mostly resolved on continued treatment.&nbsp;<br />&nbsp;<br />Tabulated list of adverse reactions Within the following table, adverse reactions are ranked under the MedDRA frequency classification:&nbsp;<br />&nbsp;<br />Very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000), not known (cannot be estimated from the available data).&nbsp;<br />&nbsp;<br />Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.&nbsp;<br />&nbsp;<br /><strong>&nbsp;Table 1. Adverse reactions with roflumilast in clinical COPD studies and post-marketing experience&nbsp;</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Frequency </strong><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypersensitivity</p></td><td style="vertical-align:top"><p>Angioedema</p></td></tr><tr><td style="vertical-align:top"><p>Endocrine disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Gynaecomastia</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>Weight decreased Decreased appetite</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>Insomnia</p></td><td style="vertical-align:top"><p>Anxiety</p></td><td style="vertical-align:top"><p>Suicidal ideation and behaviour* Depression Nervousness</p><p>Panic attack</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>Tremor Vertigo Dizziness</p></td><td style="vertical-align:top"><p>Dysgeusia</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Palpitations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Respiratory tract infections (excluding Pneumonia)</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Diarrhoea Nausea Abdominal pain</p></td><td style="vertical-align:top"><p>Gastritis Vomiting</p><p>Gastro-esophageal reflux disease Dyspepsia</p></td><td style="vertical-align:top"><p>Haematochezia Constipation</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Gamma-GT increased Aspartate aminotransferase (AST) increased</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rash</p></td><td style="vertical-align:top"><p>Urticaria</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Muscle spasms and weakness</p><p>Myalgia Back pain</p></td><td style="vertical-align:top"><p>Blood creatine phosphokinase (CPK) increased</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Malaise Asthenia Fatigue</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>Description of selected adverse reactions * In clinical studies and post-marketing experience, rare instances of suicidal ideation and behaviour, including suicide, were reported. Patients and caregivers should be instructed to notify the prescriber of any suicidal ideation (see also section 4.4).&nbsp;<br />&nbsp;<br />Other special populations A higher incidence of sleep disorders (mainly insomnia) in patients &ge;75 years or older was observed in Study RO-2455-404-RD for patients treated with roflumilast when compared to those treated with placebo (3.9% vs 2.3%). The incidence observed was also higher in patients less than 75 years old, treated with roflumilast when compared to those treated with placebo (3.1% vs 2.0%).&nbsp;<br />&nbsp;<br />A higher incidence of sleep disorders (mainly insomnia) in patients with a baseline body weight &lt;60 kg was observed in Study RO-2455-404-RD for patients treated with roflumilast when compared to those treated with placebo (6.0% vs 1.7%). The incidence was 2.5% vs 2.2% in patients with a baseline body weight &ge;60 kg, treated with roflumilast when compared to those treated with placebo.&nbsp;<br />&nbsp;<br />Concomitant treatment with long acting muscarinic antagonists (LAMA) A higher incidence of weight decrease, decreased appetite, headache and depression was observed during Study RO-2455-404-RD in patients receiving concomitant roflumilast and long-acting muscarinic antagonists (LAMA) plus concomitant inhaled corticosteroids (ICS) and long acting B2 agonists (LABA) compared to those treated only with concomitant roflumilast, ICS and LABA.&nbsp;<br />&nbsp;<br />Difference of incidence between roflumilast and placebo was quantitatively greater with concomitant LAMA for weight decreased (7.2% vs 4.2%), decreased appetite (3.7% vs 2.0%), headache (2.4% vs 1.1%) and depression (1.4% vs -0.3%).&nbsp;<br />&nbsp;<br />Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:&nbsp;</p><p>&nbsp;</p><table border="1" align="center" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p><strong>To report any side effect(s):</strong></p><p> The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>o Fax: +966-11-205-7662</p><p>o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>o&nbsp;&nbsp;&nbsp;&nbsp; Toll free phone: 8002490000</p><p>o&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>o&nbsp;&nbsp;&nbsp;&nbsp; Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Symptoms In Phase I studies, the following symptoms were observed at an increased rate after single oral doses of 2,500 micrograms and one single dose of 5,000 micrograms (ten times the recommended dose): headache, gastrointestinal disorders, dizziness, palpitations, lightheadedness, clamminess and arterial hypotension.&nbsp;<br />&nbsp;<br />Management In case of overdose, it is recommended that the appropriate supportive medical care is provided. Since roflumilast is highly protein bound, haemodialysis is not likely to be an efficient method of its removal. It is not known whether roflumilast is dialysable by peritoneal dialysis.&nbsp;<br />&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Drugs for obstructive airway diseases, other systemic drugs for obstructive airway diseases, ATC code: R03DX07&nbsp;<br />&nbsp;<br />Mechanism of action Roflumilast is a PDE4 inhibitor, a non-steroid, anti-inflammatory active substance designed to target both the systemic and pulmonary inflammation associated with COPD. The mechanism of action is the inhibition of PDE4, a major cyclic adenosine monophosphate (cAMP)metabolizing enzyme found in structural and inflammatory cells important to the pathogenesis of COPD. Roflumilast targets the PDE4A, 4B and 4D splicing variants with similar potency in the nanomolar range. The affinity to the PDE4C splicing variants is 5 to 10-fold lower. This mechanism of action and the selectivity also apply to roflumilast N-oxide, which is the major active metabolite of roflumilast.&nbsp;<br />&nbsp;<br />Pharmacodynamic effects Inhibition of PDE4 leads to elevated intracellular cAMP levels and mitigates COPD-related malfunctions of leukocytes, airway and pulmonary vascular smooth muscle cells, endothelial and airway epithelial cells and fibroblasts in experimental models. Upon in vitro stimulation of human neutrophils, monocytes, macrophages or lymphocytes, roflumilast and roflumilast Noxide suppress the release of inflammatory mediators e.g. leukotriene B4, reactive oxygen species, tumor necrosis factor &alpha;, interferon &gamma; and granzyme B. In patients with COPD, roflumilast reduced sputum neutrophils. Furthermore, roflumilast attenuated influx of neutrophils and eosinophils into the airways of endotoxin challenged healthy volunteers.&nbsp;<br />&nbsp;<br />Clinical efficacy and safety In two confirmative replicate one-year studies (M2-124 and M2-125) and two supplementary six-month studies (M2-127 and M2-128), a total number of 4,768 patients were randomized&nbsp;&nbsp;and treated of whom 2,374 were treated with roflumilast. The design of the studies was parallel-group, double-blind and placebo-controlled.&nbsp;<br />&nbsp;<br />The one-year studies included patients with a history of severe to very severe COPD [FEV1 (forced expiratory volume in one second) &le;50% of predicted] associated with chronic bronchitis, with at least one documented exacerbation in the previous year and with symptoms at baseline as determined by cough and sputum score. Long-acting beta-agonists (LABAs) were allowed in the studies and were used in approximately 50% of the study population. Short-acting anticholinergics (SAMAs) were allowed for those patients not taking LABAs. Rescue medicinal products (salbutamol or albuterol) were allowed on an as-needed basis. The use of inhaled corticosteroids and theophylline was prohibited during the studies. Patients with no history of exacerbations were excluded.&nbsp;<br />&nbsp;<br />In a pooled analysis of the one-year studies M2-124 and M2-125, roflumilast 500 micrograms once daily significantly improved lung function compared to placebo, on average by 48 ml (pre-bronchodilator FEV1, primary endpoint, p&lt;0.0001), and by 55 ml (post-bronchodilator FEV1, p&lt;0.0001). The improvement in lung function was apparent at the first visit after 4 weeks and was maintained up to one year (end of treatment period). The rate (per patient per year) of moderate exacerbations (requiring intervention with systemic glucocorticosteroids) or severe exacerbations (resulting in hospitalisation and/or leading to death) after 1 year was 1.142 with roflumilast and 1.374 with placebo corresponding to a relative risk reduction of 16.9% (95% CI: 8.2% to 24.8%) (primary endpoint, p=0.0003). Effects were similar, independent of previous treatment with inhaled corticosteroids or underlying treatment with LABAs. In the subgroup of patients with history of frequent exacerbations (at least 2 exacerbations during the last year), the rate of exacerbations was 1.526 with roflumilast and 1.941 with placebo corresponding to a relative risk reduction of 21.3% (95%CI: 7.5% to 33.1%). Roflumilast did not significantly reduce the rate of exacerbations compared with placebo in the subgroup of patients with moderate COPD.&nbsp;<br />&nbsp;<br />The reduction of moderate or severe exacerbations with roflumilast and LABA compared to placebo and LABA was on average 21% (p=0.0011). The respective reduction in exacerbations seen in patients without concomitant LABAs was on average 15% (p=0.0387). The numbers of patients who died due to any reason were equal for those treated with placebo or roflumilast (42 deaths each group; 2.7% each group; pooled analysis).&nbsp;<br />&nbsp;<br />A total of 2,690 patients were included and randomized in two supportive 1-year studies (M2111 and M2-112). In contrast to the two confirmative studies, a history of chronic bronchitis and of COPD exacerbations was not requested for patients&#39; inclusion. Inhaled corticosteroids were used in 809 (61%) of the roflumilast treated patients, whereas the use of LABAs and theophylline was prohibited.&nbsp;<br />&nbsp;<br />Roflumilast 500 micrograms once daily significantly improved lung function compared to placebo, on average by 51 ml (pre-bronchodilator FEV1, p&lt;0.0001), and by 53 ml (postbronchodilator FEV1, p&lt;0.0001). The rate of exacerbations (as defined in the protocols) were not significantly reduced by roflumilast in the individual studies (relative risk reduction: 13.5%in study M2-111 and 6.6% in study M2-112; p= not significant). Adverse events rates were independent of concomitant treatment with inhaled corticosteroids.&nbsp;<br />&nbsp;<br />Two six-month supportive studies (M2-127 and M2-128) included patients with a history of COPD for at least 12 months prior to baseline. Both studies included moderate to severe patients with a non-reversible airway obstruction and a FEV1 of 40% to 70% of predicted. Roflumilast or placebo treatment was added to continuous treatment with a long-acting bronchodilator, in particular salmeterol in study M2-127 or tiotropium in study M2-128. In the two six-month studies, pre-bronchodilator FEV1 was significantly improved by 49 ml (primary endpoint, p&lt;0.0001) beyond the bronchodilator effect of concomitant treatment with salmeterol in study M2-127 and by 80 ml (primary endpoint, p&lt;0.0001) incremental to concomitant treatment with tiotropium in study M2-128.&nbsp;<br />&nbsp;<br />Study RO-2455-404-RD was a one year study in COPD patients with a baseline (prebronchodilator) FEV1 &lt;50% of predicted normal and a history of frequent exacerbations. The study assessed the effect of roflumilast on COPD exacerbation rate in patients treated with fixed combinations of LABA and inhaled corticosteroids, compared to placebo. A total of 1935 patients were randomised to double-blind medication and approximately 70% were also using a long-acting muscarinic antagonist (LAMA) through the course of the trial. The primary endpoint was reduction in rate of moderate or severe COPD exacerbations per patient per year. The rate of severe COPD exacerbations and changes in FEV1 were evaluated as key secondary endpoints.&nbsp;<br />&nbsp;</p><p><strong>Table 2. Summary of COPD exacerbation endpoints in Study RO-2455-404-RD&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>Exacerbation </strong><strong>Category</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>Analysis </strong><strong>model</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>Roflumilast </strong><strong>(N=969)</strong></p><p><strong>Rate (n)</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>Placebo </strong><strong>(N=966)</strong></p><p><strong>Rate (n)</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Ratio Roflumilast/Placebo</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>2-Sided p- </strong><strong>value</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Rate </strong><strong>Ratio</strong></p></td><td style="vertical-align:top"><p><strong>Change </strong><strong>(%)</strong></p></td><td style="vertical-align:top"><p><strong>95% CI</strong></p></td></tr><tr><td style="vertical-align:top"><p>Moderate or severe</p></td><td style="vertical-align:top"><p>Poisson regression</p></td><td style="vertical-align:top"><p>0.805 (380)</p></td><td style="vertical-align:top"><p>0.927</p><p>(432)</p></td><td style="vertical-align:top"><p>0.868</p></td><td style="vertical-align:top"><p>-13.2</p></td><td style="vertical-align:top"><p>0.753,</p><p>1.002</p></td><td style="vertical-align:top"><p>0.0529</p></td></tr><tr><td style="vertical-align:top"><p>Moderate</p></td><td style="vertical-align:top"><p>Poisson regression</p></td><td style="vertical-align:top"><p>0.574 (287)</p></td><td style="vertical-align:top"><p>0.627</p><p>(333)</p></td><td style="vertical-align:top"><p>0.914</p></td><td style="vertical-align:top"><p>-8.6</p></td><td style="vertical-align:top"><p>0.775,</p><p>1.078</p></td><td style="vertical-align:top"><p>0.2875</p></td></tr><tr><td style="vertical-align:top"><p>Severe</p></td><td style="vertical-align:top"><p>Negative binomial regression</p></td><td style="vertical-align:top"><p><em>&nbsp;</em></p><p>0.239 (151)</p></td><td style="vertical-align:top"><p>0.315</p><p>(192)</p></td><td style="vertical-align:top"><p><em>&nbsp;</em></p><p>0.757</p></td><td style="vertical-align:top"><p><em>&nbsp;</em></p><p>-24.3</p></td><td style="vertical-align:top"><p>0.601,</p><p>0.952</p></td><td style="vertical-align:top"><p><em>&nbsp;</em></p><p>0.0175</p></td></tr></tbody></table><p>&nbsp;</p><p>There was a trend towards a reduction in moderate or severe exacerbations in subjects treated with roflumilast compared with placebo over 52 weeks, which did not achieve statistical significance (Table 2). A pre-specified sensitivity analysis using the negative binomial regression model treatment showed a statistically significant difference of -14.2% (rate ratio: 0.86; 95% CI: 0.74 to 0.99).&nbsp;<br />&nbsp;<br />The per-protocol Poisson regression analysis and the non-significant sensitivity to drop-out Poisson regression intention-to-treat analysis rate ratios were 0.81 (95% CI: 0.69 to 0.94) and 0.89 (95% CI: 0.77 to 1.02), respectively There was a trend towards a reduction in moderate or severe exacerbations in subjects treated with roflumilast compared with placebo over 52 weeks, which did not achieve statistical significance (Table 2). A pre-specified sensitivity analysis using the negative binomial regression model treatment showed a statistically significant difference of -14.2% (rate ratio: 0.86; 95% CI: 0.74 to 0.99).&nbsp;<br />&nbsp;<br />The per-protocol Poisson regression analysis and the non-significant sensitivity to drop-out Poisson regression intention-to-treat analysis rate ratios were 0.81 (95% CI: 0.69 to 0.94) and 0.89 (95% CI: 0.77 to 1.02), respectively</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Roflumilast is extensively metabolised in humans, with the formation of a major pharmacodynamically active metabolite, roflumilast N-oxide. Since both roflumilast and roflumilast N-oxide contribute to PDE4 inhibitory activity in vivo, pharmacokinetic considerations are based on total PDE4 inhibitory activity (i.e. total exposure to roflumilast and roflumilast N-oxide).&nbsp;<br />&nbsp;<br />Absorption The absolute bioavailability of roflumilast following a 500 micrograms oral dose is approximately 80%. Maximum plasma concentrations of roflumilast typically occur approximately one hour after dosing (ranging from 0.5 to 2 hours) in the fasted state&nbsp;Maximum concentrations of the N-oxide metabolite are reached after about eight hours (ranging from 4 to 13 hours). Food intake does not affect the total PDE4 inhibitory activity, but delays time to maximum concentration (tmax) of roflumilast by one hour and reduces Cmax by approximately 40%. However, Cmax and tmax of roflumilast N-oxide are unaffected.&nbsp;<br />&nbsp;<br />Distribution Plasma protein binding of roflumilast and its N-oxide metabolite is approximately 99% and 97%, respectively. Volume of distribution for single dose of 500 micrograms roflumilast is about 2.9 l/kg.&nbsp;<br />&nbsp;<br />Due to the physico-chemical properties, roflumilast is readily distributed to organs and tissues including fatty tissue of mice, hamster and rat. An early distribution phase with marked penetration into tissues is followed by a marked elimination phase out of fatty tissue most probably due to pronounced break-down of parent compound to roflumilast N-oxide. These studies in rats with radiolabeled roflumilast also indicate low penetration across the blood-brain barrier. There is no evidence for a specific accumulation or retention of roflumilast or its metabolites in organs and fatty tissue.&nbsp;<br />&nbsp;<br />Biotransformation Roflumilast is extensively metabolised via Phase I (cytochrome P450) and Phase II (conjugation) reactions. The N-oxide metabolite is the major metabolite observed in the plasma of humans. The plasma AUC of the N-oxide metabolite on average is about 10-fold greater than the plasma AUC of roflumilast. Thus, the N-oxide metabolite is considered to be the main contributor to the total PDE4 inhibitory activity in vivo.&nbsp;<br />&nbsp;<br />In vitro studies and clinical interaction studies suggest that the metabolism of roflumilast to its N-oxide metabolite is mediated by CYP1A2 and 3A4. Based on further in vitro results in human hepatic microsomes, therapeutic plasma concentrations of roflumilast and roflumilast N-oxide do not inhibit CYP1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, 3A4/5, or 4A9/11. Therefore, there is a low probability of relevant interactions with substances metabolised by these P450 enzymes. In addition, in vitro studies demonstrated no induction of the CYP1A2, 2A6, 2C9, 2C19, or 3A4/5 and only a weak induction of CYP2B6 by roflumilast.&nbsp;<br />&nbsp;<br />Elimination The plasma clearance after short-term intravenous infusion of roflumilast is about 9.6 l/h. Following an oral dose, the median plasma effective half-life of roflumilast and its N-oxide metabolite are approximately 17 and 30 hours, respectively. Steady state plasma concentrations of roflumilast and its N-oxide metabolite are reached after approximately 4 days for roflumilast and 6 days for roflumilast N-oxide following once-daily dosing. Following intravenous or oral administration of radiolabelled roflumilast, about 20% of the radioactivity was recovered in the faeces and 70% in urine as inactive metabolites.&nbsp;<br />&nbsp;<br />Linearity/Non-linearity The pharmacokinetics of roflumilast and its N-oxide metabolite are dose-proportional over a range of doses from 250 micrograms to 1,000 micrograms&nbsp;Special populations In older people, females and in non-Caucasians, total PDE4 inhibitory activity was increased. Total PDE4 inhibitory activity was slightly decreased in smokers. None of these changes were considered to be clinically meaningful. No dose adjustment is recommended in these patients. A combination of factors, such as in black, non-smoking females, might lead to an increase of exposure and persistent intolerability. In this case, roflumilast treatment should be reassessed (see section 4.4).&nbsp;<br />&nbsp;<br />In study RO-2455-404-RD when compared with the overall population, the total PDE4 inhibitory activity determined from ex vivo unbound fractions was found to be 15% higher in patients &ge;75 years of age, and 11% higher in patients with baseline body weight &lt;60 kg (refer to section 4.4).&nbsp;<br />&nbsp;<br />Renal impairment Total PDE4 inhibitory activity decreased by 9% in patients with severe renal impairment (creatinine clearance 10-30 ml/min). No dose adjustment is necessary.&nbsp;<br />&nbsp;<br />Hepatic impairment The pharmacokinetics of roflumilast 250 micrograms once-daily was tested in 16 patients with mild to moderate hepatic impairment classified as Child-Pugh A and B. In these patients, the total PDE4 inhibitory activity was increased by about 20% in patients with Child-Pugh A and about 90% in patients with Child-Pugh B. Simulations suggest dose proportionality between roflumilast 250 and 500 micrograms in patients with mild and moderate hepatic impairment. Caution is necessary in Child-Pugh A patients (see section 4.2). Patients with moderate or severe hepatic impairment classified as Child-Pugh B or C should not take roflumilast (see section 4.3).&nbsp;<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no evidence for an immunotoxic, skin sensitising or phototoxic potential.&nbsp;<br />&nbsp;<br />A slight reduction in male fertility was seen in conjunction with epididymal toxicity in rats. No epididymal toxicity or changes in semen parameters were present in any other rodent or nonrodent species including monkeys in spite of higher exposures.&nbsp;<br />&nbsp;<br />In one of two rat embryofetal development studies, a higher incidence of incomplete skull bone ossification was seen at a dose producing maternal toxicity. In one of three rat studies on fertility and embryofetal development, post-implantation losses were observed. Postimplantation losses were not seen in rabbits. Prolongation of gestation was seen in mice.&nbsp;<br />&nbsp;<br />The relevance of these findings to humans is unknown.&nbsp;<br />&nbsp;<br />Most relevant findings in safety pharmacology and toxicology studies occurred at higher doses and exposure than that intended for clinical use. These findings consisted mainly of&nbsp;&nbsp;gastrointestinal findings (i.e. vomiting, increased gastric secretion, gastric erosions, intestine inflammation) and cardiac findings (i.e. focal haemorrhages, haemosiderin deposits and lympho-histiocytic cell infiltration in the right atria in dogs, and decreased blood pressure and increased heart rate in rats, guinea pigs and dogs).&nbsp;<br />Rodent-specific toxicity in the nasal mucosa was observed in repeat-dose toxicity and carcinogenicity studies. This effect seems to be due to an ADCP (4-Amino-3,5-dichloropyridine) N-oxide intermediate specifically formed in rodent olfactory mucosa, with special binding affinity in these species (i.e. mouse, rat and hamster).&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The other ingredients are: &nbsp;- Core: Lactose BP 200, Maize Starch, Povidone 30, and Magnesium Stearate. - Coating: Hydroxypropyl Methylcellulose, Titanium Dioxide Pharma Grade, Polyethylene Glycol MW 6000, Purified Talc, Iron Oxide Yellow and Purified Water BP</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24Months/2 Years 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Reel OPA/AL/PVC &nbsp;Each pack contains 30 tablets&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                SPIMACO AlQassim pharmaceutical plant Saudi Pharmaceutical Industries & Medical Appliance Corporation 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                February 2017. 
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>